Stemcell Therapeutics (SSS.V) (SCTPF) also targets the CD47 but with SIRPaf and may be even better than Stanfords approach. They are presenting on april 9 at AACR14
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.